News room - Egetis Therapeutics

26 June, 2020 Positive pre-clinical results with PledOx to be presented at Peripheral Nerve Society’s annual meeting News Corporate Information Other Corporate Information English IR Optional

24 June, 2020 Marie-Louise Alamaa appointed interim CFO at PledPharma News Corporate Information Staff change English Regulatory Listing Regulation IR Optional

26 May, 2020 CFO Yilmaz Mahshid leaves PledPharma News Corporate Information Staff change English Regulatory Listing Regulation IR Optional

11 May, 2020 PledPharma receives US patent for method of treatment related to calmangafodipir News Corporate Information Other Corporate Information English IR Optional

23 April, 2020 Kommuniké från årsstämman i PledPharma AB (publ) News Corporate Information General meeting Report of the AGM English Regulatory Listing Regulation IR Optional

22 April, 2020 Interim report January-March 2020 News English Regulatory MAR Report Interim Q1 IR Optional

6 April, 2020 PledPharma to close POLAR phase 3 program in the third quarter News Corporate Action Other English Regulatory MAR IR Optional

2 April, 2020 Information on the Annual General Meeting and Covid-19 News Corporate Information Other Corporate Information English IR Optional

30 March, 2020 PledPharma’s 2019 annual report published News Corporate Information Other Corporate Information English Regulatory Listing Regulation IR Optional

25 March, 2020 KALLELSE TILL ÅRSSTÄMMA I PLEDPHARMA AB News Corporate Information General meeting Notice English Regulatory Listing Regulation IR Optional

1 March, 2020 PledPharma places dosing of patients in the POLAR program on hold News Corporate Information Other Corporate Information English Regulatory MAR IR Optional mfn-cus-pledox

18 February, 2020 Year-end report January-December 2019 News English Regulatory MAR Report Interim Yearend IR Optional

23 January, 2020 PledPharma provides update on the clinical POLAR program, clinical hold in the US News Corporate Information Other Corporate Information English Regulatory MAR IR Optional mfn-cus-pledox

8 January, 2020 PledPharma to initiate one pivotal Phase II/III study with Aladote® for marketing authorisation application in both US and EU News Corporate Information Other Corporate Information English IR Optional mfn-cus-aladote

Press releases

2020

Calendar and upcoming reports

Contact us

Press releases

2020

Calendar and upcoming reports

Subscribe

Contact us